Table 3.

Summary of studies describing the clinical relevance of CHD4 expression as a biomarker of prognosis in different breast cancer patients.

No. patients	Type of breast cancer	CHD4 expression	Clinical relevanceTherapeutical implications	Reference
208	Breast cancer Oncomine database	mRNA levels & immunostaining	High expression of CHD4 correlates with low expression of p21. High expression of CHD4 is a biomarker of poor prognosis. CHD4 may be a useful target in the treatment of BRCA-proficient BC cells.	(25)
60	TNBC	Immunostaining	Higher CHD4 expression is positively correlated with metastatic stage, tumor recurrence, and survival status. High CHD4 expression at the level of mRNA and protein significantly correlated with shorter survival.	(26)
51	TNBC Ualcan and Oncomine database	Immunostaining	Low co-expression of CHD4 levels and β1 integrin correlated with better overall survival. Integrin inhibitors might benefit patients with TNBC and high CDH4 expression levels.	(27)
382	TNBC	mRNA	High CHD4 expression positively correlated with HIF target genes and poor overall survival CHD4 is a powerful candidate in the development of new anti-cancer agents in TNBC.	(28)